Immutep's Efti Shows Excellent Survival Data from INSIGHT-003 Trial in Non-Small Cell Lung Cancer
Portfolio Pulse from
Immutep Limited announced positive results from its INSIGHT-003 Phase I trial, showing excellent survival data for its drug eftilagimod alpha in combination with KEYTRUDA and chemotherapy for non-small cell lung cancer. The trial showed a median overall survival of 32.9 months and a 24-month overall survival rate of 81.0%.
November 14, 2024 | 1:30 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Immutep Limited's INSIGHT-003 trial shows promising results for eftilagimod alpha in combination with KEYTRUDA and chemotherapy, indicating potential for improved treatment in non-small cell lung cancer.
The positive trial results for Immutep's eftilagimod alpha in combination with KEYTRUDA and chemotherapy suggest a significant advancement in treatment for non-small cell lung cancer. This could lead to increased investor confidence and a potential rise in stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100